Illumina Feb 5, 2026 Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025 - Yahoo Finance
FierceBiotech Feb 5, 2026 Racing BMS and J&J, Bayer links asundexian to 26% stroke reduction to unblock path to FDA
Endpoints News Feb 5, 2026 #ISC26: Bayer’s asundexian reduced ischemic strokes by 26% in Phase 3 trial
10x Genomics Blog Feb 5, 2026 10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Finviz